124 related articles for article (PubMed ID: 23272673)
1. Palliative care opportunities for women with advanced ovarian cancer associated with intraperitoneal chemotherapy.
Otis-Green S; Wakabayashi MT; Morgan R; Hakim A; Ferrell B; Sun V; Yang E; Grant M
J Palliat Med; 2013 Jan; 16(1):44-53. PubMed ID: 23272673
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
Rowan K
J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
[No Abstract] [Full Text] [Related]
5. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
6. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal Chemotherapy: The Lived Experiences of Taiwanese Patients With Ovarian Cancer.
Chou JF; Lu Y
Clin J Oncol Nurs; 2019 Dec; 23(6):E100-E106. PubMed ID: 31730595
[TBL] [Abstract][Full Text] [Related]
8. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
Kothari R; Nagel C; Koopmeiners JS; Ivy JJ; Geller M; Salani R; Argenta PA
Gynecol Oncol; 2010 Dec; 119(3):491-5. PubMed ID: 20888625
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
[TBL] [Abstract][Full Text] [Related]
10. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of quality of life in patients with advanced ovarian cancer treated with intraperitoneal or intravenous cisplatin and cyclophosphamide as a second line of therapy].
Majdak E; Krasińska L; Mielcarek P; Kobierski J; Kozaka J; Milczek T; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1096-102. PubMed ID: 12722405
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
13. Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.
Burkett AM; Cohn DE; Copeland LJ
Gynecol Oncol; 2007 Feb; 104(2):491-3. PubMed ID: 17150244
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
15. A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.
Markman M
Gynecol Oncol; 2007 Jun; 105(3):561-2. PubMed ID: 17428522
[No Abstract] [Full Text] [Related]
16. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
[TBL] [Abstract][Full Text] [Related]
18. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
Chen YL; Liu YQ; Tang DH; Chu CN
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749
[TBL] [Abstract][Full Text] [Related]
20. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
